Cornu, Marjorie
Bruno, Bénédicte
Loridant, Séverine
Navarin, Pauline
François, Nadine
Lanternier, Fanny
Amzallag-Bellenger, Elisa
Dubos, François
Mazingue, Françoise
Sendid, Boualem
Funding for this research was provided by:
CHRU de Lille-bonus H
Article History
Received: 4 September 2018
Accepted: 21 November 2018
First Online: 6 December 2018
Ethics approval and consent to participate
: Basilea Pharmaceutica International Ltd., provided the medication for compassionate use in the context of a Temporary Authorization for Use which was granted by the French National Agency for Medicines and Health Products Safety. Its authorization has been obtained after a multidisciplinary consultation meeting.In this context, the parents of the child were informed and gave their consent for compassionate use of isavuconazole.
: Written informed consent for publication of their clinical details and/or clinical images was obtained from the parent of the patient. A copy of the consent form is available for review by the Editor of this journal.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.